EE05191B1 - Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine - Google Patents
Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamineInfo
- Publication number
- EE05191B1 EE05191B1 EEP200200245A EEP200200245A EE05191B1 EE 05191 B1 EE05191 B1 EE 05191B1 EE P200200245 A EEP200200245 A EE P200200245A EE P200200245 A EEP200200245 A EE P200200245A EE 05191 B1 EE05191 B1 EE 05191B1
- Authority
- EE
- Estonia
- Prior art keywords
- tolterodine
- hours
- active ingredient
- relates
- pharmaceutical formulation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 title abstract 3
- 229960004045 tolterodine Drugs 0.000 title abstract 3
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE1999/002052 WO2000027364A1 (en) | 1998-11-11 | 1999-11-11 | New controlled release bead, a method of producing the same and multiple unit formulation comprising it |
SE0000782A SE0000782D0 (sv) | 1999-11-11 | 2000-03-09 | Pharmaceutical formulation and its use |
PCT/SE2000/002061 WO2001034139A1 (en) | 1999-11-11 | 2000-10-24 | Pharmaceutical formulation containing tolterodine and its use |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200245A EE200200245A (et) | 2003-06-16 |
EE05191B1 true EE05191B1 (et) | 2009-08-17 |
Family
ID=56290073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200245A EE05191B1 (et) | 1999-11-11 | 2000-10-24 | Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine |
Country Status (24)
Country | Link |
---|---|
US (1) | US6630162B1 (sl) |
EP (1) | EP1227806B1 (sl) |
JP (1) | JP2003513918A (sl) |
KR (2) | KR20070091374A (sl) |
CN (1) | CN100353935C (sl) |
AT (1) | ATE300941T1 (sl) |
AU (1) | AU784104B2 (sl) |
BR (1) | BR0015346A (sl) |
CA (1) | CA2387973C (sl) |
CZ (1) | CZ304671B6 (sl) |
DE (1) | DE60021749T2 (sl) |
DK (1) | DK1227806T3 (sl) |
EE (1) | EE05191B1 (sl) |
ES (1) | ES2245320T3 (sl) |
HK (1) | HK1054196B (sl) |
HU (1) | HUP0203028A3 (sl) |
MX (1) | MXPA02004574A (sl) |
NO (1) | NO20022264L (sl) |
NZ (1) | NZ518309A (sl) |
PL (1) | PL356166A1 (sl) |
PT (1) | PT1227806E (sl) |
SI (1) | SI1227806T1 (sl) |
SK (1) | SK6412002A3 (sl) |
WO (1) | WO2001034139A1 (sl) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
JP2003513918A (ja) * | 1999-11-11 | 2003-04-15 | フアーマシア・アー・ベー | トルテロジン含有医薬組成物及びその使用 |
AU2002360717A1 (en) * | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Controlled release dosage form having improved drug release properties |
DE10224556A1 (de) * | 2002-05-31 | 2004-01-08 | Grünenthal GmbH | 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen |
EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
WO2004054560A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
JP2006515607A (ja) * | 2003-01-22 | 2006-06-01 | ファイザー・ヘルス・アクチエボラーグ | 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 |
SE0300830D0 (sv) * | 2003-03-26 | 2003-03-26 | Pharmacia Ab | New formulations and use thereof |
DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
EP1635795A1 (en) * | 2003-05-30 | 2006-03-22 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
EP1629834A1 (en) † | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
CN100382794C (zh) * | 2004-08-30 | 2008-04-23 | 鲁南制药集团股份有限公司 | 酒石酸托特罗定的分散片剂型 |
CN1795845B (zh) * | 2004-12-23 | 2010-10-13 | 李又欣 | 作为毒蕈碱受体拮抗剂的3,3-二苯基丙胺衍生物注射用缓释微球制剂 |
CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
EP2015735A1 (en) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodine beads |
CZ2006506A3 (cs) * | 2006-08-09 | 2007-10-03 | Zentiva, A. S. | Farmaceutická kompozice s obsahem tolterodinu |
KR100851033B1 (ko) * | 2007-02-12 | 2008-08-12 | 명문제약주식회사 | 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법 |
KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
EP2173329A1 (en) * | 2007-07-03 | 2010-04-14 | Synthon B.V. | Tolterodine bead |
US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
EP2175843B1 (en) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
WO2009080061A1 (en) * | 2007-12-20 | 2009-07-02 | Pharmathen S.A. | Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof |
US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
CA2753416A1 (en) * | 2009-02-23 | 2010-08-26 | Gopi Venkatesh | Controlled release compositions comprising anti-cholinergic drugs |
EP2459180A1 (en) * | 2009-07-31 | 2012-06-06 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
SG174658A1 (en) * | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
CA2796877A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
US8392016B2 (en) | 2010-06-25 | 2013-03-05 | LNT PM Inc. | Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts |
JP6068447B2 (ja) | 2011-05-10 | 2017-01-25 | セラヴィダ,インコーポレイテッド | 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ |
EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
MX2017003561A (es) * | 2014-08-22 | 2017-08-28 | Medipath Inc | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. |
MX2018008694A (es) | 2016-01-20 | 2019-05-15 | Theravida Inc | Metodos y composiciones para tratar la hiperhidrosis. |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1144911B (it) | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
DE69326848T2 (de) | 1992-05-13 | 2000-01-27 | Alza Corp | Oxybutynin zur transdermalen Verabreichung |
SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
JPH0710745A (ja) * | 1993-06-22 | 1995-01-13 | Tanabe Seiyaku Co Ltd | 放出開始時間制御型腸デリバリー経口製剤 |
JP3453186B2 (ja) * | 1994-04-14 | 2003-10-06 | 共和薬品工業株式会社 | 徐放性マイクロカプセルおよびその製造方法 |
SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
AU7994694A (en) | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US6310103B1 (en) * | 1996-07-19 | 2001-10-30 | Bridge Pharma, Inc. | S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders |
CA2266070A1 (en) | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
JPH11193271A (ja) * | 1997-10-31 | 1999-07-21 | Ss Pharmaceut Co Ltd | アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬 |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
EP2153825A1 (en) * | 1998-08-27 | 2010-02-17 | Pfizer Health AB | Therapeutic formulation for administering tolterodine with controlled release |
SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
JP2003513918A (ja) * | 1999-11-11 | 2003-04-15 | フアーマシア・アー・ベー | トルテロジン含有医薬組成物及びその使用 |
-
2000
- 2000-10-24 JP JP2001536139A patent/JP2003513918A/ja active Pending
- 2000-10-24 CA CA002387973A patent/CA2387973C/en not_active Expired - Lifetime
- 2000-10-24 BR BR0015346-0A patent/BR0015346A/pt not_active Application Discontinuation
- 2000-10-24 NZ NZ518309A patent/NZ518309A/en not_active IP Right Cessation
- 2000-10-24 KR KR1020077019051A patent/KR20070091374A/ko not_active Application Discontinuation
- 2000-10-24 KR KR1020027005973A patent/KR100838930B1/ko active IP Right Grant
- 2000-10-24 AT AT00975092T patent/ATE300941T1/de not_active IP Right Cessation
- 2000-10-24 EP EP00975092A patent/EP1227806B1/en not_active Revoked
- 2000-10-24 EE EEP200200245A patent/EE05191B1/xx unknown
- 2000-10-24 DK DK00975092T patent/DK1227806T3/da active
- 2000-10-24 SK SK641-2002A patent/SK6412002A3/sk not_active Application Discontinuation
- 2000-10-24 SI SI200030727T patent/SI1227806T1/sl unknown
- 2000-10-24 AU AU13192/01A patent/AU784104B2/en not_active Expired
- 2000-10-24 CN CNB008154740A patent/CN100353935C/zh not_active Expired - Lifetime
- 2000-10-24 HU HU0203028A patent/HUP0203028A3/hu not_active Application Discontinuation
- 2000-10-24 MX MXPA02004574A patent/MXPA02004574A/es active IP Right Grant
- 2000-10-24 PL PL00356166A patent/PL356166A1/xx not_active Application Discontinuation
- 2000-10-24 DE DE60021749T patent/DE60021749T2/de not_active Revoked
- 2000-10-24 CZ CZ2002-1617A patent/CZ304671B6/cs not_active IP Right Cessation
- 2000-10-24 WO PCT/SE2000/002061 patent/WO2001034139A1/en active IP Right Grant
- 2000-10-24 PT PT00975092T patent/PT1227806E/pt unknown
- 2000-10-24 ES ES00975092T patent/ES2245320T3/es not_active Expired - Lifetime
- 2000-11-09 US US09/708,428 patent/US6630162B1/en not_active Expired - Lifetime
-
2002
- 2002-05-13 NO NO20022264A patent/NO20022264L/no not_active Application Discontinuation
-
2003
- 2003-09-11 HK HK03106497.2A patent/HK1054196B/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05191B1 (et) | Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine | |
MXPA02005536A (es) | Acidos aminopropilfosfinicos novedosos. | |
LU90956I2 (fr) | Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique | |
ME00520B (me) | Levodop/karbidop/entakapon farmaceutski preparat | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
MX9504034A (es) | Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas. | |
DK0668863T3 (da) | Quinuclidinderivat som substans P-antagonist | |
BG102857A (en) | Antimycotic substance-containing and acetate buffer-containing compositions | |
EP0779889A4 (en) | PYRAZOLO 3,4-g] QUINOXALINE COMPOUNDS INHIBITING FCDP RECEPTOR PROTEIN TYROSINE KINASE | |
IL148874A0 (en) | Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them | |
SE0102440D0 (sv) | New compound | |
CA2005980A1 (en) | Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation | |
NO179094C (no) | Fremgangsmåte for fremstilling av et farmasöytisk preparat for påföring på slimhinnen | |
TR200102087T2 (tr) | Yeni morfolinbenzamid tuzları | |
IE780217L (en) | 1,3,5-triazine-2,6-dione derivatives | |
MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
SE0000782D0 (sv) | Pharmaceutical formulation and its use | |
MXPA02006034A (es) | Formas de dosis mucosaloral de apomorfina. | |
SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
IT1306186B1 (it) | Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale | |
MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
DK0541726T3 (da) | Vækstfaktorsammensætninger, fremstilling og anvendelse | |
BR9915009A (pt) | Composto, composição farmacêutica, método de estimular a liberação do hormÈnio do crescimento da pituitária de um mamìfero, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR0214644A (pt) | Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HD1A | Correction of address | ||
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |